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 ABSTRACT 
DOCOSAHEXAENOIC ACID MODULATES CLASS I 
MAJOR HISTOCOMPATIBILITY PROTEIN 
FUNCTION 
By Kaleb Marie Hypes 
 
Fatty acids influence immune responses, but how this occurs at the molecular level is not 
understood.  Class I major histocompatibility complex molecules (MHC I), 
transmembrane proteins required for antigen presentation to T cell receptors, each consist 
of a 45kDa α chain noncovalently associated with a 12-kDa β2-microglobulin (β2m) 
molecule.  Docosahexaenoic acid’s (DHA) effect on the binding of β2m and anti-MHC I 
monoclonal antibodies (Mab) was measured.  EL4 and RMA-S cells were cultured 48 
hours with 0-45µM DHA or oleic acid.  Murine to human β2m exchange and Mab 
binding were assessed by fluorescence flow cytometry.  DHA-treated cells showed 
increased fluorescence (greater β2m binding and Mab binding) compared to untreated and 
oleic acid-treated cells.  The addition of α-tocopherol to these fatty acid treatments 
eliminated the DHA-associated increase in fluorescence.  DHA’s effect on the cell 
membrane may alter the conformation of MHC I affecting antigen presentation to CD8+ 
T-lymphocytes and altering immune response. 
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INTRODUCTION 
 
  The objective of this study was to examine the effects of docosahexaenoic 
acid (DHA) on the structure and function of class I major histocompatibility complex 
(MHC I) proteins.  This was accomplished by examining murine to human β2-
microglobulin exchange, anti-MHC I monoclonal antibody binding, and peptide-induced 
MHC I expression in DHA-treated cells as compared to untreated and oleic acid treated 
cells. 
 
Major Histocompatibility Complex (MHC): 
 
 The immune system relies on many regulatory mechanisms that govern its ability 
to respond to infectious agents, and one such mechanism is the MHC.  The MHC has 
long been known to be involved in the rejection of organ and bone marrow transplants.  
In the mid-1930s, Gorer and Snell determined that a molecule in foreign tissue caused the 
rejection of transplants (1).  It was first believed that this molecule was a soluble antigen 
that stimulated an immune response.  It was not until much later, in the 1970’s, that 
Zinkernagel observed that the soluble antigen alone was not enough to stimulate an 
immune response, but that antigen had to be accessible through another molecule, MHC 
proteins (2).  Eventually, it was learned that MHC proteins have many important 
functions including the control and development of CD8+ T cells, the induction of self 
tolerance in the thymus, immune surveillance against pathogens and tumors, and the 
acceptance or rejection of transplants (3). 
 The genes responsible for coding the MHC proteins (MHC genes) are located on 
a long continuous stretch of DNA on chromosome 6 in humans and chromosome 17 in 
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mice (1).  These genes encode three major classes of MHC molecules.  Class I MHC 
molecules are glycoproteins found on all nucleated cells that present peptide antigens to 
CD8+ T cells.  CD8+ T lymphocytes, or cytotoxic T lymphocyte (CTL), are generally 
distinguishable by the CD8 membrane glycoproteins on their cell surface.  CTLs target 
and destroy cells whose MHC I molecules display “foreign,” or non-self, antigens.  The 
CTL has a vital function in eliminating virus-infected cells, tumor cells, and cells of a 
foreign tissue graft.  Class II MHC molecules are expressed primarily on such antigen-
presenting cells as macrophages, dendritic cells, and B cells.  MHC II molecules present 
exogenous peptides to CD4+ T cells.  These T cells, referred to as T helper cells, are 
generally distinguishable by the CD4 membrane glycoproteins on their cell surface.  T 
helper cells recognize antigen-MHC II complexes and secrete cytokines.  These cytokines 
help to activate B cells, CTLs, and macrophages that then participate in the immune 
response.  Class III MHC genes encode secreted proteins that have immune functions, 
including components of the complement pathway and molecules involved in 
inflammation (1).   
 Human class I MHC molecules have been named human leukocyte antigen 
(HLA), and there are three different forms of HLA molecules, HLA-A, HLA-B and 
HLA-C.  There are also three different forms of murine H-2 class I MHC molecules, H-
2D, H-2K, and H-2L.  The H-2 molecules can be further distinguished by haplotype, that 
is, the set of alleles of linked genes present on one parental chromosome (1).  An 
individual receives one maternal haplotype and one paternal haplotype.  These haplotypes 
are co-dominantly expressed, which yields a very high degree of polymorphism among 
the H-2 molecules (1).  Inbred mice are homozygous at the H-2 locus because the 
 3
maternal and paternal haplotypes are identical; therefore all offspring express identical 
haplotypes.  The MHC haplotype expressed by these strains of inbred mice is designated 
by an arbitrary superscript (H-2b, H-2d) (1).   
 The MHC class I molecule is comprised of a polymorphic 45-kDa heavy chain, a 
non-covalently associated 12-kDa protein called β2-microglobulin (β2m) and a short 
peptide of 8-10 amino acids in length.  Class I chains require full assembly with β2m and 
peptide to be stably expressed on the cell membrane (4). The heavy chain is made up of 
three distinct domains, α1, α2, and α3, each containing approximately 90 amino acids 
(1).  The α1 and α2 domains form the peptide-binding groove where the peptide antigen 
is bound (Fig. 1).  MHC I molecules also have an alpha helical transmembrane region of 
about 25 hydrophobic amino acids followed by a short stretch of hydrophilic amino acids, 
and finally a short cytoplasmic tail made up of 30 amino acids (1).   
 
                          
Figure 1.  The class I MHC molecule.  MHC I consists of a 45-kDa heavy chain and a 12-kDa light chain 
(β2m), a hydrophobic transmembrane region, a cytoplasmic tail.  The heavy chain is comprised of three 
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extracellular domains: α1, α2, and α3. Disulfide bonds are present where indicated.  Figure taken from 
Reference 1.  
               
Throughout the presentation of antigenic peptide by MHC I to T cell receptors 
(TCR) (Fig. 2), the peptide and several amino acid residues of the MHC I α-chain contact 
the TCR (5).  Consequently, the conformation of the α-chain is critical in interacting with 
the TCR.  The three-dimensional structure of membrane-bound H2-Kb shows that the 
extracellular portion of MHC I is positioned on the membrane such that β2m is in contact 
with the lipid layer while the peptide binding groove faces away from the membrane 
toward the TCR (6).  Given that MHC I is a transmembrane protein and its extracellular 
domains come in contact with the plasma membrane, it is important to understand how 
lipids in the plasma membrane may affect the structure and thus the function of MHC I. 
 
 
 
 
 
 
 
Figure 2.  Schematic of an antigen presenting cell (APC) interacting with a CD8+ T cell.  The T cell 
receptor (TCR) of the CD8+ T cell is binding to the α1/α2/peptide complex while the CD8 receptor of the 
CD8+ T cell binds to the α3 domain of MHC I.  Figure adapted from Reference 1. 
 
CD8+ T Cell 
APC MHC 
TCR 
CD8 
Ag 
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β2-microglobulin: 
β2-microglobulin is the 12-kDa protein that is non-covalently associated with 
MHC class I heavy chain.  Until recently, it was thought that β2m was required for the 
proper folding and expression of MHC I on the cell surface.  The general consensus was 
that in the absence of β2m, MHC molecules underwent architectural editing in the 
endoplasmic reticulum (ER) and were lost to cytosolic degradation.  However, functional 
class I molecules do assemble with peptides in the absence of β2m and form CD8+ T cell 
epitopes (7).  These β2m-free MHC I molecules permit the development of CD8+ T cells 
that are able to elicit a lytic response and mediate tumor-specific immunity as well as 
transplant rejection (7).   
Murine β2m can readily exchange with human β2m and bovine β2m.  In fact, both 
human and bovine β2m have a higher affinity for murine class I MHC molecules than 
does murine β2m (8).  Many in vitro studies using murine systems culture cells in the 
presence of fetal bovine serum (FBS), which is a rich source of bovine β2m.  Thus, 
problems in interpretation could occur if it assumed that the murine cells studied possess 
fully murine MHC I molecules.  It is for this reason that all cells used in this study were 
cultured in serum-free medium in the absence of any exogenous β2m.   
It has been observed that the rate of β2m exchange on cell surface class I MHC 
molecules varies widely depending on the peptide ligand’s structure and affinity (9).  
This finding indicates that there is significant “cross-talk” between the peptide binding 
and β2m binding regions of the MHC I heavy chain (9).  It also tells us that there is a 
range of MHC I “structure” that is acceptable to the cells and apparently functional.   
Peptide: 
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 The α1 and α2 domains of the class I heavy chain form a peptide binding groove 
made up of a platform of antiparallel β-pleated sheets and two alpha helices (1).  The 
dimensions of the peptide-binding groove is about 1 x 2.5 nm and it can accommodate a 
peptide of 8-10 amino acids in length (10).  These peptides are tightly bound in the 
groove.  Both N and C termini of the peptide interact with MHC residues deep within the 
groove (10).  Certain side chains of peptide amino acids interact with corresponding 
MHC residues forming pockets that vary in location and shape depending on the allelic 
form of the molecule.  Thus, the polymorphism of class I MHC molecules is reflected in 
the peptide binding groove’s specificity.  It has been shown that each MHC class I allelic 
product has its own peptide preference (10).  For instance, H2-Kb molecules 
accommodate peptides of 8 amino acids in length whose anchor residues are often 
phenylalanine (position 5) and leucine (position 8) (10).  The natural ligands of the 
molecule were found to include RGYVYQGL (11), SIINFEKL (12), and HIYEFPQL 
(13). 
 In general, class I MHC peptides are derived from processed endogenous proteins 
that bind to newly synthesized heavy chain within the ER.  Intracellular proteins are 
targeted for degradation by ubiquitination and degraded into peptide pieces by 
proteasomes.  Peptides are then transported from the cytosol into the lumen of the rough 
ER by TAP (transporter associated with antigen processing) by a process that requires the 
hydrolysis of ATP.  From there, the peptides assemble with class I MHC molecules aided 
by chaperone molecules.  Calnexin, a resident membrane protein in the ER, binds to a 
free class I α chain and promotes its folding.  When β2m binds to the α chain, calnexin is 
released, and the class I complex associates with calreticulin and with the TAP-associated 
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protein tapasin.  Tapasin draws the TAP transporter into proximity with the class I 
molecule and allows it to acquire an antigenic peptide (Fig. 3). 
 
       
Figure 3.  Endogenous peptide processing through cytosolic pathway.  The proteasome degrades an 
intracellular protein into peptide pieces.  Peptides are then transported by TAP into the rough ER lumen 
where tapasin brings TAP in close proximity with the MHC I complex so that peptide may bind in the 
peptide groove.  Figure taken from Reference 1. 
 
However, exogenous peptides can also bind to class I heavy chains (14).  This 
finding is critical in the function of peptide-based vaccines (15) and may also be 
important in the “peptide regurgitation” pathway of antigen presentation (16) in which 
processed antigen is released from the cells and binds to MHC I on the cell surface.   
 The exact mechanism by which exogenous peptide binds to class I MHC 
molecules is not yet fully understood, but several pathways have been proposed.  First, 
the cell must degrade these exogenous peptides, and this is proposed to occur through any 
of three pathways.  First, the peptides could be released from endosomes into the cytosol 
and degraded by proteasomes leading to their transport by TAP into the ER.  Second, the 
peptides could be degraded and loaded in endosomes containing recycled surface MHC I.  
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Third, the peptide could be degraded inside the endosome and then regurgitated back 
outside of the cell where they bind class I molecules (17). 
 Once processed, the exogenous peptides must be presented by class I molecules.  
One proposed mechanism by which this might occur is that the peptides bind to class I 
complexes in a pre-Golgi compartment, promoting their release to the cell surface (17).  
Another possibility is that exogenous peptides bind empty class I molecules on the cell 
surface or exchange with low-affinity peptides (18).  Also, it has recently been shown 
that incubation with exogenous peptides in TAP-deficient cells can induce the release of 
nascent class I molecules from the ER, suggesting that the peptide acts inside the ER to 
induce MHC I maturation from the ER to the cell surface (17).  It is known that 
exogenous peptides can enter into intracellular compartments in a TAP-independent way 
(19).  Within these ER compartments, the peptides can bind to de novo-synthesized class 
I molecules (18).  Again, the exact role of exogenous peptide presentation by MHC I in 
the immune response is not yet understood. 
 
Docosahexaenoic acid: 
Docosahexaenoic acid (DHA) is an ω-3 polyunsaturated fatty acid (PUFA) with 
22-carbons and 6 double bonds (Fig. 4).  DHA is the longest and most unsaturated PUFA 
found commonly in biological systems, and is found in abundance in marine fish oils.  
The positive effects of the dietary intake of DHA were first observed during an 
epidemiological study of Arctic Inuit Eskimos that showed a low incidence of coronary 
heart disease.  Since the Eskimo diet consisted primarily of marine mammals and fish, it 
was deduced that some component in the marine diet, which is not prevalent in a Western 
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diet, was exhibiting protective effects against certain diseases such as heart disease 
(20,21).  Since then, DHA’s presence has been positively linked to the prevention or 
treatment of numerous human diseases such as heart disease (22), cancer (23), 
rheumatoid arthritis (24), asthma (25), lupus (26), alcoholism (27) and many others. 
 
 
 
                             Figure 4.  Molecular Structure of DHA. 
 
 Omega-3 fatty acids are named such due to the position of the last double bond 
being three carbons from the methyl (or omega) end of the acyl chain.  In nature, DHA is 
produced by unicellular algae through a complex series of elongation and desaturation 
reactions.  Marine crustaceans called copepods then consume these algae, and fish 
consume the copepods leading to high amounts of DHA in fish oils (28).   
 In mammals, DHA is only found in abundance in certain tissues, such as 
synaptosomes (29), sperm (30), and the retinal rod outer segment (31).  In these 
membranes, DHA can approach 50 mol% of the total phospholipid acyl chains (32).  
Limited tissue distribution of high DHA levels implies a specialized but undefined role 
for DHA in these cells (33).  The high levels of DHA in these tissues are not changed by 
increased dietary intake of DHA (32).  However, in other tissues where DHA is often 
found below 5 mol% of the total phospholipid acyl chains, DHA can be enriched two to 
ten fold through dietary supplementation (32).  It is in these diet-sensitive cells that DHA 
probably exhibits its numerous health benefits (33).   
O 
CH 
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 DHA readily incorporates into a variety of cells, predominantly into the 
phospholipids of the plasma membrane (23) and mitochondria (34, 35).  It is estimated 
that DHA prefers phosphatidylethanolamine over phosphatidylcholine by about 5.7 times 
in T27A leukemic cells (33).  Once incorporated into the cell membrane, DHA has 
dramatic effects on membrane stability, fluidity, and permeability.   
DHA’s multiple rigid double bonds causes distortion in the packing of 
phospholipid acyl chains.  Consequently, there is a reduction in intra- and inter-molecular 
van der Waal’s interactions, which subsequently decreases membrane stability (33).  An 
increase in plasma membrane fluidity in animal models and cultured cells has also been 
associated with DHA enrichment (36, 37, 38, 39).  DHA increases membrane 
permeability two to three fold more than oleic acid (40).  This increase in permeability is 
probably due to the wedge shape of DHA-containing phospholipids (small head group 
and wide acyl tail) (41).  The looser packing of lipids in the membrane would allow 
deeper penetration of water and solutes into the lipid bilayer (41).  The looser packing 
may also favor the insertion, movement, clustering, or conformational change of proteins 
into DHA-rich portions of the membrane (42). 
The effect of DHA incorporation into various phospholipids on membrane protein 
function is not yet fully understood.  DHA’s effect on membrane properties may cause 
changes in the properties of membrane proteins.  Such changes could affect the function 
of the protein.  The effects of DHA on several membrane proteins, including rhodopsin, 
have been thoroughly studied.   
Rhodopsin is a membrane protein of the rod photoreceptor cell in the retina of the 
eye.  It catalyses the only light sensitive step in vision.  When light is absorbed, a change 
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in the conformation of rhodopsin triggers a sequence of reactions that leads to a nerve 
impulse. This is transmitted to the brain via the optical nerve.  The presence of DHA in 
these cell membranes was found to enhance the light-triggered conformational change in 
rhodopsin thereby enhancing the initial neuronal response of the eye to light (43). 
This study will focus on the effect that the incorporation of DHA into 
phospholipids has on the structure and function of the transmembrane protein MHC I. 
 
Objective: 
 The objective of this study is to examine the effects of cellular DHA 
incorporation on MHC I expression, conformation and function as shown by monoclonal 
antibody, β2m, and peptide binding.  My hypothesis is that the various membrane effects 
of DHA will cause the transmembrane protein MHC I to have an altered conformation 
thereby affecting the function of the molecule.  It is also possible that the emergence of 
MHC I onto the cell surface will be altered by DHA enrichment (44,45).  The overall 
goal of this work is to shed light on how the effects of DHA on MHC I may alter immune 
response in such a way as to prevent cancer and autoimmune disease. 
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MATERIALS 
 
The following materials and equipment were used during this research and are organized 
below by descriptive categories.  
 
Antibodies and Labels: 
• Biotin-conjugated mouse anti-mouse H-2Kb monoclonal antibody, clone AF6-
88.5 (#553568), BD Pharmingen, Palo Alto, California. 
• Fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse H-2Kb 
monoclonal antibody, clone AF6-88.5 (#553569), BD Pharmingen. 
• Biotin-conjugated mouse anti-mouse H-2Db monoclonal antibody, clone 28-14-8 
(#553601), BD Pharmingen. 
• Biotin-conjugated mouse IgG2b, κ monoclonal immunoglobulin isotype control 
(#559531), BD Pharmingen. 
• FITC-conjugated mouse IgG2b, κ monoclonal immunoglobulin isotype control 
(#559532), BD Pharmingen. 
• Streptavidin-allophycocyanin conjugate (#554067), BD Pharmingen. 
• Goat anti-mouse IgG (whole molecule), FITC conjugate, affinity-isolated 
antibody (#F2012), Sigma-Aldrich, St. Louis, Missouri.   
• Monoclonal anti-human Beta-2-microglobulin, clone BM-63 (#M7398), Sigma-
Aldrich. 
• Beta-2-microglobulin from human urine (#M-4890), Sigma. 
 
Cell Culture: 
• EL4 cell line, American Type Culture Collection, Manassas, Virginia (#TIB-39, 
strain C57BL/6N). 
• RMA-S cells graciously provided by Dr. Peter Cresswell (Professor of 
Immunobiology and Cell Biology, Yale University) and Dr. Ted Hansen 
(Professor of Genetics, Pathology and Immunology, Washington University) 
• HyQ-CCM 1 serum-free medium for hybridomas, HyClone, Logan, Utah  
(#SH30043), stored at 4°C.   
• Medium supplemented with 100 units penicillin G and 100 µg streptomycin per 
ml (Gibco BRL Life Technologies, #15140). 
• Phosphate buffered saline, pH 7.2, Gibco Invitrogen, #20012-027. 
• Bovine serum albumin (#A-7906), Sigma. 
• Trypan blue, Sigma, #T6146. 
• α-Tocopherol (#T 3251), Sigma. 
• Peptide SIINFEKL (serine, isoleucine, isoleucine, asparagine, phenylalanine, 
glutamic acid, lysine, leucine), Biomer Technology, Concord, California (#3J17-
2-MSA). 
 
Fatty Acids: 
• DHA, Nu-Chek Prep, Elysian, Minnesota, #U-84-A. 
• Oleic acid, Nu-Chek Prep, #U-46-A. 
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• Hexane used as solvent (29-325-3), Aldrich, Milwaukee, Wisconsin. 
 
 
Reagents: 
• Absolute Ethanol (E702-3), Aldrich.  
 
 
Equipment: 
• Pipetters.  Rainin Pipetman.  1000 µl capacity, # P-1000; 200 µl capacity, # P-
200, 20 µl capacity, # P-20. 
• Vortex.  Fisher Genie 2.  Fisher Scientific, Pittsburgh, Pennsylvania, # 12-812. 
• Centrifuge.  IEC Centra CL3R.  International Eqipment Company, Needham 
Heights, Massachusetts, # 3755. 
• Flow Cytometer.  Epics Altra.  Beckman Coulter, Inc., Miami, Florida, # 
6605563. 
• Pipet pump.  Drummond Pipet-aid.  Drummopnd Scientific Company, Broomall, 
Pennsylvania, # 4-000-110. 
• Laminar flow hood.  Safeaire biological safety cabinet.  Fisher Hamilton L.L.C., 
Two Rivers, Wisconsin, # 54L392. 
• Incubator.  Humidified incubator, set to 37.5°C with 5% CO2.  Heraeus 
Instruments, South Plainfield, New Jersey, # B-5060. 
 
Supplies: 
• Small cell culture flasks.  Falcon 50-ml polystyrene tissue culture treated flasks 
with plug caps.  Becton Dickinson Labware, Franklin Lakes, New Jersey.  # 
353014. 
• Large cell culture flasks.  75-cm2 cell culture treated flasks with plug caps.  
Corning Incorporated, Corning, New York.  # 430720. 
• Centrifuge tubes.  15-ml and 50-ml Fisherbrand polystyrene centrifuge tubes.  
Fisher Scientific. #s 05-539-2 and 05-539-10. 
• Capped culture tubes.  Fisherbrand 75-mm2 polystyrene tubes.  Fisher Scientific.  
# 202109428. 
• 5-ml glass test tubes.  Fisher Scientific. # 14-961-26. 
• Pipettes.  Costar stripette polystyrene pipettes.  Corning Incorporated.  5-ml: 
#4487; 10-ml: # 4488; 25-ml: #4489; 50-ml: # 4490. 
• Pipette tips.  Fisherbrand Redi-Tip general purpose tips.  Fisher Scientific.  
Yellow 1-200-µl tips # 21-197-8G; blue 101-1000-µl tips # 21-197-8F. 
• Tissue culture plate, 24-well, flat bottom with low evaporation lid.  Becton 
Dickinson Labware.  #353047. 
• Microcentrifuge tubes.  Fisherbrand 1.5-ml tubes. Fisher Scientific.  # 05-408-
129. 
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METHODS 
 
Cell Culture: 
In sterile 75-cm2 flasks, EL4 and RMA-S cells were cultured in serum-free 
medium supplemented with 100 units penicillin G and 100 µg streptomycin per ml in a 
humidified incubator at 5% CO2.  The cells were maintained at a passage rate of 2-3 days.  
Cells were harvested by centrifuging at 1500 rpm (450 x g) for 10 minutes.  Upon 
harvesting, cell counts were performed using a hemocytometer and trypan blue stain.  
Twenty-five microliters of 0.04% trypan blue was mixed with 25 µl of cell suspension 
and allowed to incubate for 30 seconds.  Fifty microliters of PBS was then added, and the 
cells were examined under a hemocytometer.   Cells with a viability of 90% or better 
were used in assays.   Once cells were harvested and counted, they were suspended in 
fresh serum-free medium at a concentration of approximately 1.0 x 106 cells/ml.   
 
Fatty Acid Incubation: 
Docosahexaenoic acid and oleic acid were dissolved in hexane at a concentration 
of 10 mg/ml and stored in brown vials at –30°C.  The vials were opened under a stream 
of nitrogen gas to prevent oxidation of the fatty acid.  For 1 ml of 200 µM DHA, 6.56 µl 
of DHA (in hexane) was dried under nitrogen for about 5 minutes.  The DHA was then 
dissolved in 10 µl of 100% ethanol and dripped slowly into 990 µl of serum-free medium 
while vortexing.  An additional 1 ml of serum-free medium was added for a final 
concentration of 100 µM DHA.  For 1 ml of 200 µM oleic acid, 5.75 µl of oleic acid (in 
hexane) was dried under nitrogen and dissolved in 10 µl of 100% ethanol.  It was then 
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dripped slowly into 990 µl of serum-free medium.  An additional 1 ml of serum-free 
medium was added for a final concentration of 100 µM oleic acid.   
Cells were treated with different concentrations of fatty acid in a 24-well plate for 
48 hours at 37°C.  Approximately 5.0 x 105 cells in 500 µl of serum-free medium were 
placed in each well with 0, 35, 40 and 45 µM fatty acid.  Serum-free medium was added 
to bring the final volume of each well to 1.5 ml, and 0.5% EtOH was added to each well.  
After the two-day incubation, treated cells were harvested by centrifuging at 1500 rpm 
for 10 minutes and washed in PBS containing 1% BSA.  EL4 cells were used in the 
monoclonal antibody binding assays, beta-2 microglobulin assay, MHC turnover assay, 
and the α-tocopherol assay.  RMA-S cells were used in the peptide-induced MHC I 
expression assay. 
 
Monoclonal Antibody Binding Assays: 
Once EL4 cells were treated with fatty acid and washed, they were resuspended in 
200 µl PBS with 1% BSA at a concentration of about 1.0 x 10^6 cells/ml.  One 
microgram of biotinylated anti-H-2Kb (Clone AF6-88.5) or anti-H-2Db (Clone 28-14-8) 
was added to the cell suspension that was then incubated on ice for 30 minutes.  Some 
samples used as negative controls were incubated with 1 µg of biotinylated mouse   
IgG2b, κ immunoglobulin isotype control.  The cells were centrifuged at 1500 rpm at 
room temperature for 10 minutes and washed with 500 µl PBS containing 1% BSA.  The 
cells were resuspended in 200 µl PBS with 1% BSA.  Then 0.4 µg of streptavidin-
allophycocyanin was added to the cells suspension and incubated on ice for 30 minutes.  
The cells were centrifuged at 1500 rpm at room temperature for 10 minutes and washed 
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with 500 µl PBS containing 1% BSA before being resuspended in 1ml PBS containing 
1% BSA for analysis by flow cytometry.   The samples were stored on ice and covered 
with aluminum foil for protection from light. 
Unless it is stated otherwise, all conditions for washing and resuspending the cells 
are the same in each assay, as are the approximate cell concentrations in suspension and 
the storage of the samples during analysis. 
 
Beta 2-microglobulin Binding Assay: 
Once EL4 cells were treated with fatty acid and washed, they were resuspended in 
200 µl PBS containing 1% BSA.   The cells were then incubated on ice for 30 minutes 
with 5 µg of human beta-2 microglobulin and washed again.  The human beta-2 
microglobulin was stored at -30°C in 50 µl aliquots at 0.1 µg/µl.  The cells were then 
resuspended in 200 µl PBS with 1% BSA and incubated with 1.0 µg monoclonal anti-
human beta-2 microglobulin for 30 minutes on ice.  The anti-human beta-2 microglobulin 
stock solution (1.6 mg/ml) was stored at -30°C.   Fresh 1:10 dilutions of the reagent were 
prepared for each experiment. Those samples used as negative controls were not 
incubated with anti-human beta-2 microglobulin.  Following another wash, the cells were 
resuspended in 250 µl PBS with 1% BSA and incubated with 1.1 µg FITC-conjugated 
goat anti-mouse IgG for 30 minutes on ice.  This reagent was stored at 4°C. After a final 
wash, the cells were analyzed by flow cytometry.   
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Peptide-induced MHC I expression: 
RMA-S cells were treated with DHA and oleic acid as previously described.  
After 36 hours of incubation with the fatty acids at 37°C, 500 µM (39.47 µl at 0.25 µg/µl) 
peptide (SIINFEKL) was added to the cells for the remaining 12-hour incubation.  The 
SIINFEKL peptide (serine, isoleucine, isoleucine, asparagine, phenylalanine, glutamic 
acid, lysine, leucine) was dissolved in PBS and stored at -30°C in 200 µl aliquots at a 
concentration of 0.25 µg/µl.  The cells were washed and resuspended in 200 µl PBS 
containing 1% BSA.  The cells were incubated on ice for 30 minutes with 1 µg (2.0 µl) 
FITC-conjugated anti-H-2Kb (Clone AF6-88.5) or biotinylated anti-H-2Db (Clone 28-14-
8).  After washing, the cells incubated with biotinylated 28-14-8 were incubated 30 
minutes on ice with 0.3 µg (3.0 µl) streptavidin-APC, washed again, resuspended in 1 ml 
PBS containing 1% BSA, and then analyzed by flow cytometry.  The cells incubated with 
FITC-AF6-88.5 were immediately washed, resuspended in 1 ml PBS containing 1% BSA 
and analyzed by flow cytometry.  Samples of cells from each fatty acid treatment that did 
not undergo incubation with peptide were used as negative controls. 
 
α-Tocopherol Assay: 
EL4 cells were incubated in fatty acids as described previously, except that the 
0.5% ethanol in each well contained 15 µg/ml α-tocopherol.  The cells were incubated 48 
hours at 37°C, washed, and resuspended in 200 µl PBS containing 1% BSA.  One 
microgram (2.0 µl) of biotinylated AF6-88.5 or 28-14-8 antibody was added, as well as 
1.0 µg (2.0 µl) of biotinylated isotype control antibody to the negative control samples.  
The samples were incubated on ice for 30 minutes, washed, and resuspended in 200 µl 
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PBS containing 1% BSA.  Then 0.3 µg (3.0 µl) streptavidin-allophycocyanin was added 
to each sample and incubated on ice an additional 30 minutes.  After a final wash, the 
cells were resuspended in 1 ml PBS containing 1% BSA and analyzed by flow cytometry. 
 
Flow Cytometry: 
A Beckman Coulter Altra flow cytometer with Expo32 MultiComp software was 
used to analyze all samples.  Those samples that were analyzed with an FITC-conjugated 
antibody were excited at 488 nm with an Argon laser and emitted fluorescent light in the 
525 nm range was collected, as well as forward and side scatter light.  Those samples 
labeled with the biotin-streptavidin-APC complex were excited at 633 nm with a red 
HeNe laser and fluorescence in the 675 nm range was collected, as well as forward and 
side scatter light.  In all cases, 10,000 events were collected and then analyzed using 
Expo32 Analysis Software version 1.2.  Logarithmic plots of each fatty acid treatment 
were superimposed with the corresponding control sample (untreated cells).  The control 
sample was then subtracted from each treatment plot, and the Overton percent was 
calculated by determining what percentage of the treatment plot was more positive than 
the control plot, where positive is defined as higher fluorescence.  These Overton 
percents were plotted using Sigma Plot 2000 and statistical significance (P < 0.05) was 
determined by one-way ANOVA using Sigma Stat 3.0.   
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RESULTS 
 
 
 DHA’s effect on MHC I function was measured by examining murine to human 
β2m exchange, anti-MHC I monoclonal antibody (Mab) binding, and Mab binding to 
peptide-induced MHC I on the cell surface.  EL4 and RMAS cells were cultured for 48 
hours with 0-45 µM DHA or oleic acid, and β2m binding and Mab binding were assessed 
by fluorescence flow cytometry.  DHA treated cells were compared to untreated cells by 
superimposing their histograms, which were generated by flow cytometry.  Overton 
percents were calculated by Expo32 software to determine what percentage of the 
treatment plot was more positive than the control (untreated) plot, where positive is 
defined as higher fluorescence (more binding). 
 
DHA Dose Response: 
 The optimal range of DHA concentrations was determined by a curve measuring 
response to a series of doses.  A range of 20-55 µM DHA was tested on EL4 cells (Fig. 
5).  The range of DHA concentrations used in impending experiments, 35-45 µM DHA, 
was selected based on the greatest effect on the binding of β2m, peptide and anti-MHC I 
Mab while maintaining cell viability.  This range was initially determined by the β2m 
binding assay, but proved to be optimal for Mab and peptide binding assays as well.  The 
result of 35 µM DHA treatment was 22% more fluorescence (i.e. resulted in more 
binding) than no treatment.  The 40 µM and 45 µM DHA treatments were 44% and 73% 
more fluorescent, respectively.  All logarithmic fluorescent plots were gated on viable 
cells shown by scatter plots (Fig. 6).   
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 A distinct shift in the light scatter pattern of DHA-treated cells was revealed by 
scatter plots, indicating increased size and complexity of the cellular membrane (Fig. 6).  
Cell viability decreased from 87% with no DHA to 41% with 45 µM DHA.  Oleic acid 
had no significant effect on the scatter pattern of the cells (Fig. 6). 
                                  
Figure 5.  Dose response curve for EL4 cells treated with DHA.  Cells were treated with 0-55 µM DHA for 
48 hours at 37°C.  Murine to human β2m exchange was measured for each treatment.  Logarithmic plots 
were gated on live cells as determined by scatter plots.  Overton percent was calculated using Expo32 
software by overlaying each treatment plot with the untreated plot, thus yielding the percentage of cells that 
are more positive than the control (untreated cells) where positive is defined as higher fluorescence.  This 
graph is representative of a single experiment. 
 
 
 
 
Figure 6.   Scatter plots of untreated, DHA-treated and oleic acid-treated EL4 cells.   A) Two-dimensional 
plot of forward versus side (90°) laser light scatter of untreated EL4 cells.  The gate defines the cell 
population analyzed in Figure 5 (87%). B) 45 µM DHA treated EL4 cells, 41% gated.  C) 45 µM Oleic 
acid treated EL4 cells, 78% gated.  These graphs are representative of a single experiment.   
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β2m Dose Response: 
 The optimal concentration of human β2m to be exchanged with murine β2m was 
determined by a dose response curve.  A range of 3 to 7 µg human β2m was added to EL4 
cells (Fig. 7).  The optimal amount of human β2m was determined to be 5 µg (50 µl of 
0.1 µg/µl stock solution), which was 91% more fluorescent than the negative control.         
 
Figure 7.   Human β2m  dose response curve.  A) Dose response curve for human β2m.  Human β2m (3-7 
µg) was added to EL4 cells and allowed to incubate 30 minutes on ice.  The cells were stained for β2m 
binding as previously described, and their fluorescence was measured by flow cytometry.  Overton percents 
were calculated by determining the percentage of cells in each treatment plot that were more fluorescent 
than the untreated cells.  Higher percentages (higher fluorescence) indicate increased β2m binding. B) 
Example of overlay plot.  EL4 cells were treated as described above.  Human β2m (7.0 µg) binding is 
displayed by the peak on the right.  The peak on the left displays the negative control (no human β2m 
added). 
 
 
                                                  
 
DHA increases β2m binding to MHC I on the cell surface: 
 The effect of DHA and oleic acid on β2m binding was determined by fluorescent 
flow cytometry as previously described.  β2m binding increased in a DHA dose-
dependent manner with each DHA treatment (Fig. 8).  Figure 8 is an average of 8 
experiments.  Cells treated with 35 µM DHA were an average of 48% more fluorescent 
than untreated cells.  The 40 µM and 45 µM DHA treatments were 57% and 65% more 
A B 
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fluorescent, respectively.  Of importance is the dramatic linear increase in β2m binding in 
response to DHA treatment (48-65% more fluorescent).  The increase in β2m binding is 
statistically significant and reproducible.  In contrast, the treatment with the 
monounsaturated oleic acid had no significant effect on β2m binding. 
                             
 
Figure 8.  DHA increases β2m binding to MHC I on the cell surface.   EL4 cells were treated with 0-45 µM 
DHA and oleic acid for 48 hours at 37°C.  β2m binding was assayed as previously described.  Overton 
percents were calculated by determining the percentage of cells in each treatment plot that were more 
fluorescent than the untreated cells.  Data represent average of experiments (n=8).  Error bars represent 
standard error.  *One-way ANOVA was performed on data, n=8, and each DHA dose was determined to be 
statistically different from untreated cells, P<0.05. 
 
 
DHA increases AF6-88.5 binding to MHC I on the cell surface: 
 The Mab clone AF6-88.5 binds to a conformational-epitope on the H-2Kb α 
chain.  EL4 cells were treated with fatty acid and AF6-88.5 binding was assayed by 
fluorescence flow cytometry.  DHA-treated cells showed increased fluorescence 
compared to untreated and oleic acid treated cells (Fig. 9).  Figure 9 shows the average of 
7 experiments.  Cells treated with 35 µM DHA were 34% more fluorescent than 
untreated cells.  The 40 µM and 45 µM DHA treatments were 42% and 43% more 
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fluorescent, respectively.  The fluorescence plots were gated on live cells, and to ensure 
that fluorescent antibody was not penetrating the cell, isotype control antibody binding 
was also assayed for each DHA treatment (Fig. 10).  The isotype control antibody 
binding remained at background staining levels for each DHA treatment (Fig. 10).  Of 
importance is the dramatic linear increase in AF6-88.5 binding in response to DHA 
treatment (34-43% more fluorescent).  The increase in AF6-88.5 binding is statistically 
significant and reproducible.  In contrast, the treatment with the monounsaturated oleic 
acid had no significant effect on AF6-88.5 binding. 
                              
Figure 9.  DHA increases AF6-88.5 binding to MHC I on the cell surface.  EL4 cells were treated with 0-
45 µM DHA or oleic acid and were then assayed for AF6-88.5 binding as previously described.  Cells were 
then analyzed for fluorescence by flow cytometry.  Overton percents were calculated by determining the 
percentage of cells in each treatment plot that were more fluorescent than the untreated cells.  Data 
represent average of experiments (n=7).  Error bars represent standard error.  *One-way ANOVA was 
performed on the data, n=7, and each DHA dose was determined to be statistically different from untreated 
cells, P<0.05. 
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Figure 10.  Example of overlay plots.  AF6-88.5 binding is displayed by the peak on the right, and isotype 
control binding is displayed by the peak on the left.  Overton percents were calculated by determining what 
percentage of each “positive plot” (AF6-88.5 binding) was more fluorescent than the control plot (Isotype 
control).  A) 0 µM DHA treatment, 39%  B) 35 µM DHA treatment, 85%  C) 40 µM DHA treatment, 86%  
and D) 45 µM DHA treatment, 88%. 
 
 
DHA increases 28-14-8 binding to MHC I on the cell surface: 
 The Mab clone 28-14-8 binds to a non-conformational epitope on the H-2Db α 
chain.  EL4 cells were treated with fatty acid and assayed for 28-14-8 binding as 
previously detailed.  DHA-treated cells showed increased fluorescence compared to 
untreated and oleic acid-treated cells (Fig. 11).  Cells treated with 35 µM DHA were 33% 
more fluorescent than untreated cells.  The 40 µM and 45 µM DHA treatments were 45% 
and 50% more fluorescent, respectively.  The fluorescent plots were gated on live cells, 
and to ensure that fluorescent antibody was not penetrating the cell, isotype control 
antibody binding was also assayed for each DHA treatment (data not shown).   
 25
 Of importance is the dramatic linear increase in 28-14-8 binding in response to 
DHA treatment (33-50% more fluorescent).  The increase in 28-14-8 binding is 
statistically significant and reproducible.  In contrast, the treatment with the 
monounsaturated oleic acid had no significant effect on 28-14-8 binding. 
                              
Figure 11.   DHA increases 28-14-8 binding to MHC I on the cell surface.  EL4 cells were treated with 0-
45 µM DHA and oleic acid and were then assayed for 28-14-8 binding as previously described.  Cells were 
analyzed for fluorescence by flow cytometry.  Overton percents were calculated by determining the 
percentage of cells in each treatment plot that were more fluorescent than the untreated cells.  Data 
represent average of experiments (n=5).  Error bars represent standard error.  *One-way ANOVA was 
performed on the data, n=5, and the 40 and 45 µM DHA doses were determined to be statistically different 
from untreated cells, P<0.05. 
 
 
 
DHA increases Mab binding of peptide-induced MHC I on the cell surface: 
 The mutant mouse lymphoma cell line RMA-S shows a strongly reduced cell 
surface expression of H-2 class I molecules, although heavy and light chains of class I 
molecules are synthesized normally.  This abnormality is due to the lack of the genes 
encoding TAP-2 proteins.   Because RMA-S cells are TAP-2 deficient, they do not form 
functional TAP heterodimers and hence cannot efficiently supply cytosolic peptides for 
class I assembly in the ER.  Exposure of this cell line to exogenous peptide results in the 
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increased expression of MHC I molecules on the cell surface, interpreted as peptide-
induced assembly of class I molecules in the ER and subsequent transport to the cell 
surface. 
 A peptide dose response curve was determined by exposing RMA-S cells to 300-
500 µM SIINFEKL peptide for 12 hours at 37°C.  MHC I surface expression was then 
measured by AF6-88.5 binding.  MHC I surface expression did increase in a peptide 
dose-dependent manner (Fig. 12).  The 500 µM peptide dose was chosen for further 
experiments because it yielded 74% more fluorescence than those cells that were not 
exposed to peptide.  Figure 13 shows the overlay plots of RMA-S cells exposed to 
peptide superimposed with those that were not exposed to peptide. 
                                     
Figure 12.  Peptide dose response curve.  RMA-S cells were exposed to 300 to 500 µM SIINFEKL peptide 
for 12 hours at 37°C.  After washing, the cells were incubated with FITC-conjugated AF6-88.5 and 
prepared as previously described.  Overton percents were calculated by determining what percentage of 
peptide-exposed cells was more fluorescent than non-exposed cells.  This graph is representative of one 
experiment. 
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Figure 13.  Overlay plots of peptide-exposed RMA-S cells vs. non-exposed cells.  Peak on the left 
represents non-exposed cells treated with FITC-conjugated AF6-88.5 Mab.  Peak on the right represents 
cells exposed to 500 µM SIINFEKL peptide for 12 hours at 37°C and then treated with FITC-conjugated 
AF6-88.5 Mab. 
 
 DHA and oleic acid treated cells were exposed to 500 µM SIINFEKL for 12 
hours at 37°C.  Negative control samples were not exposed to the peptide.  The cells were 
then assayed for Mab binding as previously detailed.     
DHA-treated cells showed higher fluorescence as compared to untreated and oleic 
acid-treated cells with both Mabs.  Clone AF6-88.5 recognizes a conformational epitope 
(Fig. 14), and clone 28-14-8 recognizes an epitope that is not dependent on native α chain 
conformation (Fig. 15).   Of importance is the dramatic linear increase in the binding of 
both Mabs in response to DHA treatment (9-21% more fluorescent for AF6-88.5 binding 
and 25-31% more fluorescent for 28-14-8 binding).  The increase in Mab binding is 
statistically significant and reproducible.  In contrast, the treatment with the 
monounsaturated oleic acid had no significant effect on Mab binding. 
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Figure 14.  DHA increases AF6-88.5 binding to peptide-induced MHC I on the cell surface.  RMA-S cells 
were treated with 0-45 µM DHA and oleic acid for 48 hours at 37°C.  During the last 12 hours of this 
treatment, the cells were exposed to 500 µM SIINFEKL peptide.  The cells were then assayed for AF6-88.5 
binding as previously described, and analyzed for fluorescence by flow cytometry.  Overton percents were 
calculated by determining the percentage of cells in each treatment plot that were more fluorescent than the 
untreated cells.  Data represent an average of experiments (n=6).  Error bars represent standard error.  
*One-way ANOVA was performed on the data, n=6, and it was determined that each DHA treatment was 
statistically different from the untreated cells, P<0.05.   
                            
 
Figure 15.  DHA increases 28-14-8 binding to peptide-induced MHC I on the cell surface. RMA-S cells 
were treated with DHA and peptide as previously described.  They were then assayed for 28-14-8 binding 
and analyzed for fluorescence by flow cytometry.  Overton percents were calculated by determining the 
percentage of cells in each treatment plot that were more fluorescent than the untreated cells.  Data 
represent an average of experiments (n=3).  Error bars represent standard error.  *One-way ANOVA was 
performed on the data, n=3, and it was determined that each DHA treatment was statistically different from 
the untreated cells, P<0.05.   
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α-Tocopherol eliminates DHA-associated increase of Mab binding to MHC I: 
 α-Tocopherol, commonly referred to as vitamin E, is a strong antioxidant.  To 
determine whether the effect of DHA on Mab binding assays and peptide-induced MHC I 
expression was an oxidative effect, and thus prevented by an antioxidant, 15 µg/ml of α-
tocopherol was added to the cells prior to the 48 hour fatty acid treatment.  The addition 
of α-tocopherol reversed the DHA-associated increase of Mab binding (Fig. 16 and 17) 
and peptide-induced MHC I expression (Fig. 18).   
Figure 16 shows the addition of α-tocopherol to cells analyzed with the AF6-88.5 
Mab binding assay.  The effect of 35 µM DHA was decreased with the addition of α-
tocopherol from 34% to 3% more fluorescence than untreated cells.  The 40 µM DHA 
treatment was decreased from 42% to 4%, and the 45 µM DHA treatment was decreased 
from 43% to 3%.  It is important to note the elimination of the DHA-associated increase 
in AF6-88.5 binding with the addition of α-tocopherol.   
                               
Figure 16.  Addition of α-tocopherol eliminates DHA-associated increase in AF6-88.5 binding to MHC I 
on the cell surface.  EL4 cells were treated with 0-45 µM DHA and oleic acid for 48 hours at 37°C in the 
presence of 15 µg/ml α-tocopherol.  Cells were then assayed for AF6-88.5 binding as previously detailed.  
Overton percents were calculated by determining the percentage of cells in each treatment plot that were 
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more fluorescent than the untreated cells.  Data represent average of experiments (n=2).  Error bars 
represent the range of each data point. 
  
 
Figure 17 shows the addition of α-tocopherol to the 28-14-8 Mab binding assay.  
Again, the addition of α-tocopherol eliminated the DHA-associated increase in 28-14-8 
binding that was previously seen. 
                                  
Figure 17.  Addition of α-tocopherol eliminates DHA-associated increase in 28-14-8 binding to MHC I on 
the cell surface.  EL4 cells were treated with 0-45 µM DHA and oleic acid for 48 hours at 37°C in the 
presence of 15 µg/ml α-tocopherol.  The cells were then assayed for 28-14-8 binding as previously 
described.  Overton percents were calculated by determining the percentage of cells in each treatment plot 
that were more fluorescent than the untreated cells.  Data represent average of experiments (n=2).  Error 
bars represent the range of each data point. 
 
 
 
 
Figure 18 shows the addition of α-tocopherol to the peptide-induced MHC I 
expression assay.  The addition of α-tocopherol to this assay eliminated the DHA-
associated increase in Mab binding that was previously seen (Fig. 9, 11, 14, 15). 
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Figure 18.  Addition of α-tocopherol eliminates DHA-associated increase in AF6-88.5 binding to peptide-
induced MHC I on the cell surface.  RMA-S cells were treated with 0-45 µM DHA and oleic acid for 48 
hours at 37°C in the presence of 15 µg/ml α-tocopherol.  During the last 12 hours of this treatment, the 
cells were exposed to 500 µM SIINFEKL peptide.  The cells were then assayed for AF6-88.5 binding as 
previously described.  Overton percents were calculated by determining the percentage of cells in each 
treatment plot that were more fluorescent than the untreated cells.  Data represent an average of 
experiments (n=3).  Error bars represent standard error. 
 
 
 
 
The dose response for α-tocopherol was determined by adding 0 to 22.5 µg/ml α-
tocopherol to EL4 cells being treated with 45 µM DHA.    As shown in Figure 19, as the 
amount of α-tocopherol present increased, the DHA-associated effect on AF6-88.5 
binding decreased.  For this particular experiment, the reversal of DHA’s effect seemed 
to level off at around 13% with 15 µg/ml α-tocopherol.   
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Figure 19.  α-Tocopherol dose response curve.  El4 cells were treated with 45 µM DHA in the presence of 
0 to 22.5 µg/ml α-tocopherol.  AF6-88.5 binding was measured as previously described.  Overton percents 
were calculated by determining the percentage of cells in each treatment plot that were more fluorescent 
than the untreated cells. 
 
 
 α-Tocopherol also restored the scatter pattern of DHA-treated cells (Fig. 20).  In 
the absence of α-tocopherol, 41% of DHA-treated cells were gated for fluorescence 
analysis (Fig. 6).  However, with the addition of α-tocopherol, 75% of DHA-treated cells 
were gated (Fig. 20). 
 
 
Figure 20.  Scatter plots of α-tocopherol treated EL4 cells.  A) Two-dimensional plot of forward versus 
side (90°) laser light scatter of  15 µg/µl α-tocopherol treated EL4 cells.  The gate defines the cell 
population analyzed for fluorescence (67%). B) 45 µM DHA and 15 µg/µl α-tocopherol treated EL4 cells, 
75% gated.  C) 45 µM oleic acid and 15 µg/µl α-tocopherol treated EL4 cells, 61% gated. These graphs are 
representative of a single experiment. 
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Summary of Results: 
 
 In summary, it is evident that DHA increases β2m and Mab binding.  These 
increases occur in a DHA dose-dependent manner.  The addition of α-tocopherol 
eliminates this DHA-associated effect.  The implications of these phenomena will be 
discussed later. 
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DISCUSSION 
 
The purpose of this study was to determine the effects of DHA on class I MHC 
structure and function by probing β2m binding and Mab binding to MHC I on the EL4 
cell surface and peptide-induced MHC I on the RMA-S cell surface.  EL4 and RMA-S 
cells were cultured for 48 hours with 0-45 µM DHA or oleic acid.  Murine to human β2m 
exchange and Mab binding were assessed by fluorescence flow cytometry.  Peptide-
induced MHC I expression was shown by fluorescent Mab binding after peptide-
exposure to cells.  
DHA-treated cells showed increased fluorescence compared to untreated and 
oleic acid-treated cells.  Increased fluorescence indicates an increase in β2m and Mab 
binding.  As indicated by scatter plots, DHA-treated cells showed an increase in side 
scatter, representative of an increase in cell membrane complexity (Fig. 6).  This cellular 
shift illustrates that DHA is having a dramatic effect on cell membrane properties.   
This DHA-associated effect was further demonstrated by examining peptide-
induced MHC I expression.  The TAP-deficient cell line, RMA-S, was exposed to 
exogenous peptide to induce the surface expression of MHC I molecules.  Fluorescent-
labeled anti-MHC I Mab, clones AF6-88.5 and 28-14-8, detected the presence of these 
molecules. Again, DHA-treated cells showed increased fluorescence compared to 
untreated and oleic acid-treated cells (Fig. 14, 15). 
Mab binding to MHC I was examined in two cells lines that assemble MHC I in 
very different ways.  EL4 cells undergo “normal” MHC I assembly, while RMA-S cells 
undergo MHC I assembly in a TAP-deficient mechanism.  A DHA-associated increase in 
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Mab binding was observed in both cases, which indicates that DHA’s effect operates on 
MHC I no matter how it comes to the cell surface.  At least one commonality between 
EL4 and RMA-S cells is the cell membrane.  
It was originally believed that DHA’s effect on the cell membrane was causing a 
conformational change in MHC I that resulted in increased β2m and Mab clone AF6-88.5 
binding (Fig. 8, 9).  Mab clone AF6-88.5 recognizes a conformational epitope on the H-
2Kb α chain.  However, Mab clone 28-14-8, which recognizes an epitope that is not 
dependent on native α chain conformation, also exhibits increased binding with DHA 
treated cells (Fig. 11).  Thus, if the presence of DHA in membrane lipids induces a 
conformational change in MHC I, both epitopes are affected.   
The addition of α-tocopherol to the fatty acid treatment of the cells eliminated the 
DHA-associated increase in Mab binding in both EL4 cells and RMA-S cells exposed to 
exogenous peptide (Fig. 16, 17, 18).  This result has many implications.   
α-Tocopherol is a strong antioxidant that intercalates into the cell membrane 
where it breaks the chain reaction of lipid peroxidation.  It is well known that DHA is 
easily oxidized due to its six double bonds.  The fact that the DHA-associated increase in 
Mab binding is eliminated by the addition of α-tocopherol may suggest that DHA is 
having an oxidative effect on MHC I structure and function.  However, since oxidation 
damages the cell membrane, it is unlikely that Mab binding to MHC I would increase 
under oxidative stress.  The possibility that fluorescent Mab penetrates the damaged cell 
membrane is ruled out by the isotype control antibodies used in each experiment (Fig. 
10).  
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A possible explanation for the DHA-associated increase in β2m and Mab binding 
lies in the “PrOxI” hypothesis proposed by Teoh, et al (46).  They hypothesize that the 
immunoproteasome, which is primarily responsible for generating peptides to be 
presented by MHC I molecules, targets oxidatively modified proteins for degradation 
(46).  Thus, if the oxidation of DHA is affecting nearby proteins, these proteins would be 
targeted by the immunoproteasome for degradation into peptides that would then be 
presented by MHC I.  An increase in presentable peptide might stimulate the assembly of 
class I MHC molecules to the cell surface resulting in an increase in β2m and Mab 
binding (Fig. 21).   
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Figure 21.  The protein oxidation and immunoproteasome or ‘PrOxI’ hypothesis of MHC-I antigen 
processing.  DHA may cause normal proteins to be oxidatively modified and targeted for degradation by 
the immunoproteasome.  The generated peptides are then transported into the ER by TAP and bind MHC I 
molecules.  Fully assembled MHC I molecules are then transported to the Golgi and into vesicles that 
transport them to the cell membrane.  Once on the cell surface, Mab readily binds the MHC I molecules 
(46). 
 
 
 
This hypothesis may be responsible for the DHA-associated increase in β2m and Mab 
binding to MHC I on EL4 cells.  RMA-S cells, which are TAP-deficient, are unable to 
transport peptide into the ER through a normal mechanism.  However, incubation with 
exogenous peptides in TAP-deficient cells can induce the release of nascent class I 
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molecules from the ER, suggesting that the peptide acts inside the ER to induce MHC I 
maturation from the ER to the cell surface (17).  Thus, if an abundance of peptide is 
available from the degradation of oxidatively modified proteins, this peptide would 
induce the release of class I molecules from the ER.  If such were the case in RMA-S 
cells, MHC I would be detectable on the surface of DHA-treated cells in the absence of 
exogenous peptide (SIINFEKL).  The fact that no MHC I is detectable of the surface of 
DHA-treated RMA-S cells in the absence of exogenous peptide suggests that DHA is 
affecting RMA-S MHC I molecules in some other way. 
 DHA’s effect on MHC I may be a structural effect rather than an oxidative effect.  
As seen in Figure 6, DHA has a dramatic effect on the cell membrane as represented by 
laser light side scatter.  Specifically, it is known that DHA increases membrane fluidity 
and permeability and decreases membrane stability (33, 36-40).  Since MHC I is a 
transmembrane protein, changes in these membrane properties may have an effect on 
MHC I conformation.  Such a conformational change would alter the binding specificities 
of β2m and Mabs.  It has been previously suggested by Pascale, et al. that DHA played a 
role in altering MHC I conformation as shown by Mab binding (47). 
In addition to its strong antioxidant properties, α-tocopherol also decreases 
membrane fluidity by intercalating into the cell membrane (48).  The addition of α-
tocopherol to DHA-treated cells would stabilize the membrane by decreasing membrane 
fluidity.  This effect may explain the elimination of the DHA-associated increase of β2m 
and Mab binding upon the addition of α-tocopherol to DHA-treated cells.  Figure 20 
shows the scatter patterns of cells treated with DHA in the presence of 15 µg/µl α-
tocopherol.  Compared to DHA-treated cells (with no α-tocopherol), these cells have 
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reduced membrane complexity.  α-Tocopherol prevents the effect of DHA on the cell 
membrane and prevents the DHA-associated increase in Mab binding.  This is strong 
evidence that the DHA-associated increase in β2m and Mab binding is due to DHA’s 
effect on membrane structure. 
There are other possible causes for the increase of β2m and Mab binding observed 
in DHA-treated cells that are worthy of mention.  It is possible that DHA is directly 
causing an increase in MHC I biosynthesis rather than oxidants from DHA causing an 
increase in expression as previously discussed.    
In conclusion, it is believed that this study has provided sufficient evidence that 
DHA causes an increase in β2m and Mab binding to MHC I.  It is predicted that this 
increase in binding indicates some change in MHC I (conformational or otherwise) that 
will affect the ultimate function of MHC I, which is to present antigen to CD8+ T 
lymphocytes.  These effects may alter the immune response in such a way as to prevent 
or improve the outcome of cancer and autoimmune disease.  Further research needs to be 
conducted to gather more evidence towards the exact mechanism by which DHA effects 
MHC I structure and function. 
 
Suggestions for future research: 
 This study has established that DHA does have an effect on β2m and Mab binding 
to MHC I on the cell surface, but exact mechanism by which that effect occurs is not yet 
fully understood.  Further experiments need to be performed to determine how DHA 
increases β2m and Mab binding.   
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 To determine if DHA is causing an increase in MHC I expression on the cell 
surface, the “on rate” of MHC I to the cell surface should be measured in DHA-treated 
cells versus untreated cells.  Upon exposing DHA-treated RMA-S cells to exogenous 
peptide (to induce MHC I surface expression), samples could be stained for Mab binding 
and analyzed by flow cytometry at periodic time intervals.  The rate at which MHC I 
appears in DHA-treated cells should be compared that in untreated cells.   
 Also, since the exact role of α-tocopherol in these assays has yet to be 
determined, antioxidants with different properties need to be tested.  For instance, BHT 
(butylated hydroxytoluene) is an antioxidant that does not intercalate into the cell 
membrane but does break the chain reaction of lipid peroxidation, as does α-tocopherol 
(48).  If BHT does not eliminate the DHA-associated increase in β2m and Mab binding, it 
can be assumed that DHA is not having an oxidative effect on MHC I structure and 
function.  On the other hand, another antioxidant, probucol, does enter the cell membrane 
but does not affect membrane stability or fluidity (48).  If probucol does not eliminate the 
DHA-associated increase in β2m and Mab binding, it can be assumed that DHA is 
affecting MHC I structure and function by changing membrane fluidity and stability. 
 To further explore the possibility that DHA is having an oxidative effect on MHC 
I structure and function, experiments using “pre-oxidized” DHA are being conducted.  
DHA will readily oxidize placed in an unsealed container under light for approximately 
one hour.  This “pre-oxidized” DHA is then suspended in serum-free medium and added 
to cells, which are then incubated at 37°C for 48 hours.  It is predicted that if DHA is 
having an oxidative effect on MHC I to cause an increase in β2m and Mab binding, then 
pre-oxidized DHA will cause an even greater increase in β2m and Mab binding.  
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Preliminary results suggest that the DHA-associated increase in β2m and Mab binding is 
the same as or greater than that of pre-oxidized DHA.  Again, this suggests that DHA-
associated increase in β2m and Mab binding is not due to an oxidative effect on MHC I 
structure and function. 
 Once the mechanism by which DHA affects MHC I structure and function is 
determined, further investigation into how DHA-enriched cells are able to stimulate a T 
cell response should be conducted.  This could be performed in a mouse model system 
comparing the immune response of mice on DHA-rich diets to that of mice on normal 
diets. 
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